Expert Interview
Discussing ORIC Pharmaceuticals's Rinzimetostat (ORIC-944), a PRC2 (EED) Inhibitor in Combination with Darolutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ticker(s): ORICInstitution: Prostate Cancer Foundation (PCF) / The Marcus Foundation; former leadership at Emory University School of Medicine and Johns Hopkins University School of Medicine
- Chief Science Officer and Medical Director at The Marcus Foundation; Former President & CEO of the Prostate Cancer Foundation; Medical Oncologist and Physician-Scientist
- Manages 160 patients with mCRPC
- Globally recognized KOL and one of the most influential leaders in prostate cancer research and therapeutic development; Pioneered translational research in prostate cancer immunotherapy and tumor biology, including early work demonstrating the ability to break immune tolerance in metastatic prostate cancer using GM-CSF–based vaccine strategies; Founder of the Winship Cancer Institute at Emory University (NCI-designated) and former Chief of Hematology/Oncology
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
